BIND Therapeutics and Roche collaborate on discovery of novel nanomedicines

BIND Therapeutics announced that it has entered into a research agreement with Roche to discover novel nanomedicines. The revolutionary clinical-stage nanomedicine platform company develops targeted and programmable therapeutics called Accurins. Accurins are polymeric nanoparticles that incorporate a therapeutic payload and are designed to have prolonged circulation within the bloodstream, enable targeting of the diseased tissue or cells, and provide for the controlled and timely release of the therapeutic payload. According to the press release, the collaboration will focus on combining the Accurin technology with Roche's proprietary therapeutic payloads and targeting ligands. Financial terms of the collaboration were not disclosed. Cambridge based BIND has already entered research collaborations with Amgen, Pfizer and AstraZeneca to develop Accurins based on therapeutic payloads from their product pipelines. Read the full of BIND Therapeutics Genetic Engineering & Biotechnology News The Boston Globe